RxDoctor Payments Data

Ameer Almullahassani, MD

Neurology · Fairfield, CANPI 1245473131

Payments from drug & device makers

$9,270in general payments, 2019–2025

Across 415 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Livanova USA, Inc.$970
  • Pfizer$448
  • Amneal Pharmaceuticals LLC$335
  • SK Life Science, Inc.$251
  • EMD Serono, Inc.$246
  • plus $3K from 41 others

What the payments were for

  • Speaking & faculty fees$460%
  • Travel & lodging$5666%
  • Food & beverage$8,59093%
  • Education$681%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,270 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$671,817
Medicare patients
1,256
Services billed
48,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate62$92,516
ZeposiaOzanimod Hydrochloride11$87,423
SavellaMilnacipran Hcl65$76,720
RytaryCarbidopa/Levodopa41$66,034
Lacosamide90$30,053
NeuproRotigotine24$29,507
QuliptaAtogepant19$26,362
Rivastigmine53$16,390
Memantine Hcl297$15,429
Doxepin Hcl348$13,569
Pregabalin174$13,318
Levetiracetam234$12,546
Gabapentin416$9,630
Duloxetine Hcl124$9,133
Aimovig AutoinjectorErenumab-Aooe13$8,804

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSavella, Qulipta$3,831$103,08284 claims
PfizerNurtec Odt$448$92,51662 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$335$67,39959 claims
UCB, Inc.Neupro$241$29,50724 claims
Johnson & JohnsonXarelto$170$6,96812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Fairfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →